حازم عبدالإله

استشاري الأورام والأمراض الباطنية

المؤهلات العلمية

درجة الطب والجراحة العامة من جامعة كراتشي.
1993 - 1997: الإقامة في المستشفى الإسلامي.
2005 - 2008: الزمالة في مركز الحسين للسرطان.

شهادات البورد

البورد الأردني في الأمراض الباطنية.
البورد الأردني في الأورام.

الخبرة

استشارية الأورام.
رئيس وحدة أورام الراس والرقبة.
مسؤول برنامج زمالة الأورام السريرية.
خبرة واسعة في معالجة أورام الثدي وأورام الرأس والرقبة.

العضويات

جمعية الأورام الأردنية.
جمعية الألم الأردنية.
جمعية العناية التلطيفية.
عضو في الأبحاث في مركز الحسين للسرطان في مجالات الأورام النسائية، وأورام الثدي، وأورام العيون.

الإصدارات

Abdel-Razeq, Hikmat, et al. "The impact of recently published negative erythropoiesis-stimulating agent studies on the clinical management of cancer-related anemia at a single center." Hematology/oncology and stem cell therapy 3.2 (2010): 78-83.
Abdel-Razeq, Hikmat, et al. "Inferior vena cava filters in cancer patients: to filter or not to filter." Therapeutics and Clinical Risk Management 7 (2011): 99.
Abdel-Razeq, Hikmat, et al. "Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study." Drug design, development and therapy 7 (2013): 939.
Khater, Wejdan A., et al. "The practice of withholding and withdrawing life-support measures among patients with cancer in Jordan." International journal of palliative nursing 17.9 (2011): 440-445.
Abdel-Razeq, Hikmat, et al. "Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study." Drug design, development and therapy 7 (2013): 939.
Abdel-Razeq, Hikmat, et al. "From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer." Breast cancer research and treatment 165.3 (2017): 771-777.
Fasching, Peter A., et al. "Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3." (2016): TPS624-TPS624.
Abdel-Razeq, Hikmat, et al. "Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!." Thrombosis journal 16.1 (2018): 2.
Vitamin D deficiency in women with newly-diagnosed breast cancer in Jordan; Prevalence, Clinical and Pathological correlations.
The validation of Gail Model in Jordanian women with breast cancer.
Retrospective analysis of clinicopathological features of patient with multiple primary malignancies diagnosed at king Hussein Cancer Center from 2003 to 2009.
TRIple Negative Breast Cancer PrOspective Registry in Eastern Europe, MiddLe East, and Africa Protocol 7167.
Four cycles of Adriamycin plus Cyclophosphamide (AC) followed by four cycles of Docetaxel (NSABP-B27) with concomitant Trastuzumab as neoadjuvant therapy for high risk, early-stage, HER2-positive breast cancer patients." has been accepted for publication in "OncoTargets and Therapy".

معلومات الاتصال

البريد الإلكتروني:habdulelah@khcc.jo
رقم الهاتف: 96265300460-1037